Loading clinical trials...
Loading clinical trials...
Prospective Observational Study on the Clinical Efficacy of Teclistamab in Patients With Relapsed and Refractory Multiple Myeloma in Belgium
Conditions
Interventions
Teclistamab
Locations
17
Belgium
Imelda
Bonheiden, Antwerpen, Belgium
Universitair Ziekenhuis Antwerpen (UZA)
Edegem, Antwerpen, Belgium
Grand Hôpital de Charleroi
Charleroi, Henegouwen, Belgium
EpiCURA
Hornu, Henegouwen, Belgium
CHU Ambroise Paré
Mons, Henegouwen, Belgium
Jessa Ziekenhuis
Hasselt, Limburg, Belgium
Start Date
December 1, 2024
Primary Completion Date
September 1, 2027
Completion Date
September 1, 2027
Last Updated
March 12, 2025
NCT06679101
NCT05969860
NCT06383143
NCT06870760
NCT06057402
NCT06285318
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions